Cue Biopharma (CUE) Stock Price, Quote, News & History | Benzinga

Cue Biopharma Inc (CUE) Stock Price, Quote, News & History

CUENASDAQ

Trade with Public

Trade with Public

$27.70

-1.15-3.99%

Last update: Aug 27, 1:13 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$28.85

Close

-

Volume / Avg.

95.52K / 146.29K

Day Range

$26.38 - $29.20

52 Wk Range

4.97 - 45.50

Market Cap

$201.22M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

4.73%

Days to Cover

1.63

Recent Cue Biopharma, Inc. News

Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates, causing shares to jump 20.6% in pre-market trading. Other gainers include CUE, SST, AKAN, XXII, SDOT, TEAM, ISPC, and FIVN, while BAFN, RBLX, SKBL, and RNTX were among the losers.

Avi Kapoor

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license, and new CEO.

Mohd Haider

What's Behind The Drop In Cue Biopharma Stock Today?

Cue Biopharma, Inc. (NASDAQ:CUE) shares are tumbling on Wednesday after the company announced a reverse stock split.

Alex Perry

Why Bloom Energy Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL). Other gainers include PMNT, SNYR, SNAL, HOTH, HUBC, GPRO, FCHL, SANA, and CRDO. Losers include CMCT, CUE, WHLR, and GCTK.

Avi Kapoor

Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim

Cue Biopharma stock jumps after $7.5 million milestone from Boehringer Ingelheim, with additional milestone potential and pipeline progress.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-50.05M

Investing Cash Flow (TTM)

131.00K

Financing Cash Flow (TTM)

39.82M

Free Cash Flow (TTM)

-50.17M

Capital Expenditure (TTM)

-121.00K

Net Change in Cash (TTM)

-10.10M

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$195.08M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.47

PB Ratio (TTM)

90.65

Earnings Yield % (TTM)

-102.20%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.32

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$2.50M

Total Cash

$17.39M

Debt to Equity

1.33

Issuance of Debt (TTM)

-$2.50M

Repayment of Debt (TTM)

-$2.50M

Key Statistics

Open

$28.85

Close

-

Volume / Avg.

95.52K / 146.29K

Day Range

$26.38 - $29.20

52 Wk Range

4.97 - 45.50

Market Cap

$201.22M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

50

Short Interest

4.73%

Days to Cover

1.63

About

Sector

Health Care

Industry

Biotechnology

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an an...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cue Biopharma (CUE) stock?

A

You can purchase shares of Cue Biopharma (NASDAQ:CUE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cue Biopharma (CUE) competitors?

A

Other companies in Cue Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Cue Biopharma (CUE) stock?

A

Cue Biopharma has a consensus price target of $4.43.

Q

What is the current price for Cue Biopharma (CUE)?

A

The stock price for Cue Biopharma (NASDAQ: CUE) is $27.7 last updated August 27, 2026 at 1:13 PM EDT.

Q

Does Cue Biopharma (CUE) pay a dividend?

A

There are no upcoming dividends for Cue Biopharma.

Q

When is Cue Biopharma (NASDAQ:CUE) reporting earnings?

A

Cue Biopharma does not have any upcoming earnings scheduled.

Q

Is Cue Biopharma (CUE) going to split?

A

There is no upcoming split for Cue Biopharma.

Q

What sector and industry does Cue Biopharma (CUE) operate in?

A

Cue Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.